Valeant Outbids Paladin Labs with US$78 M Offer to Acquire Afexa Life Sciences
By Hetather Cartwright
Pharma Deals Review: Vol 2011 Issue 9 (Table of Contents)
Published: 19 Sep-2011
DOI: 10.3833/pdr.v2011.i9.1547 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Valeant Pharmaceuticals has outbid rival Paladin Labs with a white knight offer to acquire Afexa Life Sciences, the maker of the Cold-FX® OTC cold and flu brand, for approximately CDN$76 M (US$78 M), which represents a 29% premium to the cash consideration offered under Paladin’s hostile bid...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS